Supply of Elevit by Bayer Australia Ltd

Administered by Department of Health, Disability and Ageing

Legislation au C2013G01298 In force Gazette

Legislation content

COMMONWEALTH OF AUSTRALIA

Department of Health and Ageing
Therapeutic Goods Administration

THERAPEUTIC GOODS ACT 1989

SECTIONS 14 and 14A NOTICE

 

On 20 August 2013, the Delegate of the Secretary of the Department of Health and Ageing gave consent, pursuant to sections 14 and 14A of the Therapeutic Goods Act 1989 (the Act), to the following:

  1. The supply, importation and exportation of the therapeutic goods or classes of therapeutic goods specified in Column 2 of the Table and with the Australian Register of Therapeutic Goods number (ARTG No.) specified in Column 3 of the Table; and
  2. Without conforming to those clauses, specified in Column 5 of the Table, of the standard, specified in the Column 4 of the Table otherwise applicable to the goods.

 

Pursuant to section 15(1) of the Act, consent is subject to the conditions specified in Column 6 of the Table and consent is given for the period specified in Column 7 of the Table, provided all other requirements of the standard are met.

 

Column 1

Column 2

Column3

Column 4

Column 5

Column 6

Column 7

Sponsor

Goods or Classes of Goods

ARTG No.

Standard

Clauses

Conditions

Period for which consent is given

Bayer Australia Ltd

Elevit

213113

TGO 78

11(a)

The goods are not required to comply with TGO 78 section 11(a) but must comply with the requirements of the British Pharmacopoeia Appendix XII C Uniformity of Weight (Mass).

 

Until further notice.

Bayer Australia Ltd

Elevit

213113

TGO 78

11(b)

The goods are not required to comply with TGO 78 section 11(b) but the average content of each active ingredient in the goods must comply with the relevant acceptance criteria included in Table 1.

Until further notice.

Bayer Australia Ltd

Elevit

213113

TGO 78

11(c)

The goods are not required to comply with TGO 78 section 11(c) but must comply with the dissolution requirements of the United States Pharmacopeia-National Formulary, Dietary Supplement Chapter <2040> Disintegration and Dissolution of Dietary Supplements’ for riboflavine (Vitamin B2) and iron.

Until further notice.

 

 Table 1: Acceptance criteria for Assay of Active ingredients

Active ingredient

Label Claim (LC)

Units for  LC

Acceptance criteria in units of  label claim 

Acceptance criteria in units of  percentage of label claim 

Thiamine (Vitamin B1, as thiamine nitrate)

1.4

mg

1.26

1.69

90.0

120.7

Riboflavine (Vitamin B2)

1.4

mg

1.26

1.69

90.0

120.7

Nicotinamide

18

mg

16.2

20.8

90.0

115.6

Pantothenic acid (Vitamin B5, as calcium pantothenate)

6

mg

5.4

7.3

90.0

121.7

Pyridoxine (Vitamin B6, as pyridoxine hydrochloride)

1.9

mg

1.71

2.30

90.0

121.1

Cyanocobalamin (Vitamin B12)

2.6

µg

2.34

3.70

90.0

142.3

Ascorbic Acid (Vitamin C)

85

mg

76.5

102.9

90.0

121.1

Cholecalciferol (Vitamin D3 200 IU)

5

µg

4.5

7.4

90.0

148.0

dl-alpha tocopherol (Vitamin E, as dl-alpha tocopheryl acetate)

18.7

mg

16.83

24.68

90.0

132.0

Biotin  (Vitamin H)

30

µg

27.0

38.0

90.0

126.7

Folic acid

800

µg

720.0

1056.0

90.0

132.0

Calcium (as calcium hydrogen phosphate anhydrous, calcium pantothenate and calcium carbonate)

125

mg

113.0

138.0

90.4

110.4

Copper (as cupric sulfate anhydrous)

1

mg

0.9

1.1

90.0

110.0

Iodine (as potassium iodide)

220

µg

198.0

253.0

90.0

115.0

Iron (as ferrous fumarate) 

60

mg

54.0

66.0

90.0

110.0

Magnesium (as magnesium oxide – heavy and magnesium stearate)

100

mg

90.0

110.0

90.0

110.0

Manganese (as manganese sulfate monohydrate)

1.9

mg

1.71

2.38

90.0

125.3

Selenium (as sodium selenite)

50

µg

45.0

55.0

90.0

110.0

Zinc (as zinc citrate trihydrate)

11

mg

9.9

12.1

90.0

110.0

 

 

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.